Halozyme Therapeutics, Inc. reiterating earnings guidance for the year 2022. For the year, the company expects net revenue to be in the range of $530 million to $560 million, GAAP operating income to be in the range of $350 million to $380 million, GAAP net income to be in the range of $270 million to $295 million and GAAP diluted EPS to be in the range of $1.90 to $2.05.